In Vivo Imaging of [60]Fullerene-Based Molecular Spherical Nucleic Acids by Positron Emission Tomography.
Antti ÄäreläTatsiana AuchynnikavaOlli MoisioHeidi LiljenbäckPutri AndrianaImran IqbalJyrki LehtimäkiJohan RajanderHarri SaloAnne RoivainenAnu J AiraksinenPasi VirtaPublished in: Molecular pharmaceutics (2023)
18 F-Labeled [60]fullerene-based molecular spherical nucleic acids (MSNAs), consisting of a human epidermal growth factor receptor 2 (HER2) mRNA antisense oligonucleotide sequence with a native phosphodiester and phosphorothioate backbone, were synthesized, site-specifically labeled with a positron emitting fluorine-18 and intravenously administrated via tail vein to HER2 expressing HCC1954 tumor-bearing mice. The biodistribution of the MSNAs was monitored in vivo by positron emission tomography/computed tomography (PET/CT) imaging. MSNA with a native phosphodiester backbone (MSNA-PO) was prone to rapid nuclease-mediated degradation, whereas the corresponding phosphorothioate analogue (MSNA-PS) with improved enzymatic stability showed an interesting biodistribution profile in vivo . One hour after the injection, majority of the radioactivity was observed in spleen and liver but also in blood with an average tumor-to-muscle ratio of 2. The prolonged radioactivity in blood circulation may open possibilities to the targeted delivery of the MSNAs.
Keyphrases
- positron emission tomography
- pet imaging
- pet ct
- computed tomography
- epidermal growth factor receptor
- high resolution
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- blood pressure
- skeletal muscle
- minimally invasive
- image quality
- single molecule
- hydrogen peroxide
- quantum dots
- dna binding
- type diabetes
- ultrasound guided
- insulin resistance
- binding protein
- pluripotent stem cells
- light emitting
- loop mediated isothermal amplification